Exclusive: San Diego biotech raises $11.7M to use cells as targeted delivery vessels for genetic medicines
Cytonus Therapeutics, a small biotech company north of San Diego, raised $11.7 million in Series A financing to engineer cells as delivery vessels for genetic medicines, including mRNA therapies and oncolytic viruses for cancer, Endpoints News has learned.
The unconventional approach flips the script on cell therapy. Rather than using the cell as a medicine itself, a partially-gutted cell transports a drug to a specified address in the body, thanks to molecular homing beacons appended to its surface.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.